neffy has potential to be the first non-injectable medicine indicated to treat allergic reactions (type I) including anaphylaxis in the U.S., if approvedSAN DIEGO – October 21, 2022 - ARS Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has accepted for review ARS’ New Drug Application...
ARS Pharmaceuticals Appoints Eric Karas as Chief Commercial Officer and Kathleen Scott as Chief Financial Officer
Appointments Further Strengthen Leadership Team to Support Launch Preparations for neffy™ (epinephrine nasal spray) SAN DIEGO - April 05, 2022 - ARS Pharmaceuticals, Inc., a biopharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions that could lead to anaphylaxis, today announced the expansion of its executive...
New Data From NeffyTM (ARS-1) Studies Profiled by AAAAI
According to data ARS Pharmaceuticals originally planned to present at the 2020 Annual Meeting of the American Academy of Allergy, Asthma & Immunology (AAAAI) before its cancellation due to the situation with coronavirus disease 2019 (COVID-19), Neffy 1 mg has the potential to be the first intranasal epinephrine spray product...
ARS Pharmaceuticals Announces the Appointment of Two New Board Members
Expansion of Board of Directors Adds Commercialization and Financial Expertise, Further Augments Clinical and Scientific Acumen of Medical and Scientific Advisory Board SAN DIEGO – June 18, 2019 – ARS Pharmaceuticals, Inc., a pharmaceutical company dedicated to empowering at-risk patients and caregivers to better protect themselves from severe allergic reactions...